Partillion Bioscience aims to broaden access to the advanced single-cell tools needed for biomedical innovation with its award-winning nanovial platform.

Market:

Emerging technologies for treatment and diagnosis rely on the use of cells to produce antibodies and other recombinant proteins. The market for monoclonal antibody discovery alone was estimated at $6.5B in 2016 and is expected to reach $10.7B by 2025. Partillion aims to penetrate the discovery market with its nanovial platform. This lab-on-a-particle system selects desired cells based on complex functions and reveals the genetic information that encodes them. The goal is to enable more labs to develop higher-performing therapies and diagnostic tests, and do it faster and cheaper.

Technology:

Partillion Bioscience’s key technology is the nanovial, a specialized hydrogel microparticle platform that enables high-throughput sorting of single cells based on their secreted products — all using standard equipment. Because instruments that sort cells are already common in the bioresearch space, the nanovial can expand the types of single-cell analyses available in just about any lab.

Advantages:

  • Sorts over 100,000 cells simultaneously
  • No specialized equipment needed
  • Single-cell resolution
  • Live cell sorting
  • Profiles cells by their function

Development Stage:

  • Advanced – Prototype

Select Publications:

Contact:

Website: www.partillion.com
Phone: (707) 529-3034
Email: joe@partillion.com

Back to Top

Portfolio Companies